Trial Profile
A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone (DRd) in Japanese Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.
- 30 Jan 2020 Planned End Date changed from 1 Apr 2020 to 15 Apr 2020.
- 20 Jun 2019 Planned End Date changed from 15 Apr 2020 to 1 Apr 2020.